PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 12:01 AM ET

Sponsor Check › Person

Asish Xavier

Related person on Form D filings · address states as listed: CA, NJ, A1, MA, PA, NY, WA · listed Dec 8, 2008 → Jun 11, 2024

22issuers
66Form D filings
2008–2024years listed

Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:56 PM ET · SEC enforcement last checked: not yet

Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.

Key records

The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.

1. Lawsuits

None found in sources searched.

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:56 PM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.

Not yet searched.

Search queued. Results are added automatically; check back later or follow this page to be notified.

3. Bankruptcies

None found in sources searched.

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:56 PM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons are made for sponsors and sponsor groups, not individual people.

5. Money to insiders and sales commissions

3 of 52 offerings report sales commissions totalling $5,651,800; 0 report finder's fees; 1 reports proceeds to related persons totalling $900,000. (includes amounts the issuer reported as estimates)

SourceOffering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell it
EDGAR ↗Jun 11, 2024 D
File 021-515688
$0$0$0None listed on this filing
EDGAR ↗Mar 17, 2023 D
File 021-476128
$0$0$0None listed on this filing
EDGAR ↗Dec 29, 2022 D
File 021-469166
$0$0$0None listed on this filing
EDGAR ↗Apr 22, 2021 D
File 021-396782
$0$0$0None listed on this filing
EDGAR ↗Jan 27, 2021 D
File 021-387450
$0$0$0None listed on this filing
EDGAR ↗Sep 28, 2020 D
File 021-376482
$0$0$0None listed on this filing
EDGAR ↗Aug 5, 2020 D
File 021-372570
$0$0$0None listed on this filing
EDGAR ↗Jul 22, 2020 D
File 021-371555
$0$0$0None listed on this filing
EDGAR ↗Apr 2, 2020 D/A
File 021-327473
$0$0$0None listed on this filing
EDGAR ↗Apr 2, 2020 D
File 021-364188
$0$0$0None listed on this filing
EDGAR ↗Oct 9, 2019 D
File 021-350688
$2,500,000$0$0Bruce Roberts BrokerCheck CRD 2359901 ↗
via Beech Hill Securities, Inc. (CRD 24771 ↗)

Byung-Chan (Ted) Moon BrokerCheck CRD 4914744 ↗
via Beech Hill Securities, Inc. (CRD 24771 ↗)

Yarone Breski BrokerCheck CRD 5785868 ↗
via Beech Hill Securities, Inc. (CRD 24771 ↗)
EDGAR ↗Jul 29, 2019 D
File 021-345261
$0$0$0None listed on this filing
EDGAR ↗Jul 11, 2019 D/A
File 021-294038
$0$0$0None listed on this filing
EDGAR ↗Dec 3, 2018 D
File 021-327013
$2,743,800 (est.)$0$0Raymond James & Associates, Inc. BrokerCheck CRD 705 ↗
EDGAR ↗Oct 11, 2018 D/A
File 021-246718
$0$0$0 (est.)None listed on this filing
EDGAR ↗Aug 24, 2018 D/A
File 021-275911
$0$0$0None listed on this filing
EDGAR ↗Aug 17, 2018 D
File 021-319505
$0$0$0None listed on this filing
EDGAR ↗Aug 2, 2017 D
File 021-291967
$0$0$0None listed on this filing
EDGAR ↗Jan 31, 2017 D
File 021-279697
$0$0$0None listed on this filing
EDGAR ↗Jan 4, 2017 D/A
File 021-254438
$0$0$0None listed on this filing
EDGAR ↗Jan 6, 2016 D
File 021-254662
$0$0$0None listed on this filing
EDGAR ↗Jul 21, 2015 D/A
File 021-235733
$0$0$900,000 (est.)None listed on this filing
EDGAR ↗Jul 13, 2015 D/A
File 021-241558
$0$0$0None listed on this filing
EDGAR ↗Feb 3, 2015 D
File 021-233381
$0$0$0None listed on this filing
EDGAR ↗Apr 23, 2014 D
File 021-216115
$0$0$0None listed on this filing
EDGAR ↗Aug 20, 2013 D
File 021-201639
$0$0$0None listed on this filing
EDGAR ↗Jul 19, 2013 D
File 021-199943
$0$0$0None listed on this filing
EDGAR ↗Jul 2, 2013 D/A
File 021-185355
$0$0$0None listed on this filing
EDGAR ↗Jun 11, 2013 D
File 021-197788
$0$0$0
Other than the payment of salaries and other compensation and benefits, no officer, director, or promoter will receive any payments from the proceeds of this offering.
None listed on this filing
EDGAR ↗Apr 1, 2013 D
File 021-194308
$0$0$0None listed on this filing
EDGAR ↗Jan 3, 2013 D
File 021-189330
$0$0$0None listed on this filing
EDGAR ↗Sep 25, 2012 D
File 021-184613
$0$0$0None listed on this filing
EDGAR ↗Jun 18, 2012 D/A
File 021-40668
$0$0$0
Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.
None listed on this filing
EDGAR ↗Jan 31, 2012 D
File 021-172696
$0$0$0None listed on this filing
EDGAR ↗Dec 22, 2011 D
File 021-170592
$0$0$0None listed on this filing
EDGAR ↗Nov 16, 2011 D
File 021-168810
$0$0$0None listed on this filing
EDGAR ↗Oct 28, 2011 D
File 021-167978
$0$0$0None listed on this filing
EDGAR ↗Sep 26, 2011 D
File 021-166388
$0$0$0None listed on this filing
EDGAR ↗Sep 1, 2011 D
File 021-165275
$0$0$0None listed on this filing
EDGAR ↗Aug 18, 2011 D
File 021-164648
$0$0$0None listed on this filing
EDGAR ↗Jul 12, 2011 D
File 021-162710
$0$0$0None listed on this filing
EDGAR ↗May 17, 2011 D
File 021-159929
$0$0$0None listed on this filing
EDGAR ↗Feb 11, 2011 D
File 021-155187
$0$0$0None listed on this filing
EDGAR ↗Feb 11, 2011 D
File 021-155188
$0$0$0None listed on this filing
EDGAR ↗Oct 28, 2010 D
File 021-149731
$0$0$0None listed on this filing
EDGAR ↗Sep 21, 2010 D/A
File 021-146206
$0$0$0None listed on this filing
EDGAR ↗Jun 25, 2010 D
File 021-144021
$0$0$0None listed on this filing
EDGAR ↗Jun 25, 2010 D
File 021-144022
$0$0$0None listed on this filing
EDGAR ↗Apr 16, 2010 D
File 021-140721
$0$0$0None listed on this filing
EDGAR ↗Apr 15, 2010 D
File 021-140699
$0$0$0None listed on this filing
EDGAR ↗Dec 17, 2009 D
File 021-69966
$0$0$0None listed on this filing
EDGAR ↗Dec 8, 2008 D
File 021-60286
$408,000$0$0Seaview Securities LLC BrokerCheck CRD 126180 ↗

As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Appears on these filings

SourceIssuerRoleFiledFormOfferingSoldInvestorsMin. investment
EDGAR ↗Bright Peak Therapeutics, Inc.DirectorJun 11, 2024D$89,999,991
similar: $500,000–$7,000,000
$89,999,99121
similar: 2–14
No minimum reported
similar: $5,000–$50,000
EDGAR ↗PAIGE.AI, Inc.DirectorMar 17, 2023D$38,999,891
similar: $829,831–$9,999,998
$19,499,8943
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗SonoThera, Inc.DirectorDec 29, 2022D$60,750,000
similar: $2,000,000–$19,999,994
$30,375,00012
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ViaCyte Inc.DirectorApr 22, 2021D$58,506,166
similar: $2,000,000–$19,999,994
$53,931,16622
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗PAIGE.AI, Inc.DirectorJan 27, 2021D$100,000,000
similar: $829,831–$9,999,998
$55,000,0163
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗ESCAPE Bio, Inc.DirectorSep 28, 2020D$73,000,000
similar: $2,000,000–$19,999,994
$73,000,00029
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ImmPACT Bio USA Inc.DirectorAug 5, 2020D$5,500,000
similar: $2,000,000–$19,999,994
$3,750,00017
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Magnolia Neurosciences CorpDirectorJul 22, 2020D$17,909,091
similar: $2,000,000–$19,999,994
$5,000,0008
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ViaCyte Inc.DirectorApr 2, 2020D$36,018,634
similar: $2,000,000–$19,999,994
$32,645,78017
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Rodeo Therapeutics CorpDirectorApr 2, 2020D/A$8,950,000
similar: $2,000,000–$19,999,994
$8,950,0009
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Adicet Bio, Inc.DirectorOct 9, 2019D$80,000,000
similar: $2,000,000–$19,999,994
$80,000,00018
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ESCAPE Bio, Inc.DirectorJul 29, 2019D$35,000,000
similar: $2,000,000–$19,999,994
$31,073,38022
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Proniras CorpDirectorJul 11, 2019D/A$4,300,000
similar: $2,000,000–$19,999,994
$4,300,0007
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Rodeo Therapeutics CorpDirectorMar 29, 2019D/A$7,949,999
similar: $2,000,000–$19,999,994
$7,949,9998
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Rodeo Therapeutics CorpDirectorDec 10, 2018D$4,571,475
similar: $2,000,000–$19,999,994
$3,685,7146
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ViaCyte Inc.DirectorDec 3, 2018D$90,021,103
similar: $2,000,000–$19,999,994
$35,833,6039
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ESCAPE Bio, Inc.DirectorOct 11, 2018D/A$63,002,700
similar: $2,000,000–$19,999,994
$63,002,70031
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ApoGen Biotechnologies, Inc.DirectorAug 24, 2018D/A$7,565,892
similar: $2,000,000–$19,999,994
$7,565,89224
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Magnolia Neurosciences CorpDirectorAug 17, 2018D$13,090,909
similar: $2,000,000–$19,999,994
$8,000,00011
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Proniras CorpDirectorSep 5, 2017D$2,800,000
similar: $2,000,000–$19,999,994
$2,800,0007
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Rodeo Therapeutics CorpDirectorAug 2, 2017D$5,900,000
similar: $2,000,000–$19,999,994
$5,354,0008
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ESCAPE Bio, Inc.DirectorJun 2, 2017D/A$63,000,000
similar: $829,831–$9,999,998
$46,002,70032
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗PhaseBio Pharmaceuticals IncDirectorJan 31, 2017D$7,875,000
similar: $2,000,000–$19,999,994
$6,615,0009
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Lodo Therapeutics CorpDirectorJan 4, 2017D/A$19,867,600
similar: $2,000,000–$19,999,994
$19,867,60013
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ApoGen Biotechnologies, Inc.DirectorDec 8, 2016D$7,315,892
similar: $2,000,000–$19,999,994
$3,815,89223
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Petra Pharma CorpDirectorJan 6, 2016D$10,410,478
similar: $2,000,000–$19,999,994
$9,992,20012
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Lodo Therapeutics CorpDirectorJan 4, 2016D$3,658,304
similar: $2,000,000–$19,999,994
$3,517,60013
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ESCAPE Bio, Inc.DirectorAug 31, 2015D$55,002,700
similar: $829,831–$9,999,998
$20,002,7006
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗PhaseBio Pharmaceuticals IncDirectorJul 21, 2015D/A$42,000,000
similar: $2,000,000–$19,999,994
$21,000,0009
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗CATALYST BIOSCIENCES INCDirectorJul 13, 2015D/A$2,000,000
similar: $2,000,000–$19,999,994
$1,890,93810
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗CATALYST BIOSCIENCES INCDirectorJun 11, 2015D$1,000,000
similar: $2,000,000–$19,999,994
$1,000,00010
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗PhaseBio Pharmaceuticals IncDirectorMar 12, 2015D$40,000,000
similar: $2,000,000–$19,999,994
$20,000,0008
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗CATALYST BIOSCIENCES INCDirectorFeb 3, 2015D$5,000,000
similar: $2,000,000–$19,999,994
$3,224,99311
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗CATALYST BIOSCIENCES INCDirectorApr 23, 2014D$5,009,841
similar: $2,000,000–$19,999,994
$5,009,84118
similar: 2–16
$3,000
similar: $10,000–$50,000
EDGAR ↗CATALYST BIOSCIENCES INCDirectorAug 20, 2013D$800,008
similar: $2,000,000–$19,999,994
$400,00411
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ViaCyte Inc.DirectorJul 19, 2013D$27,175,642
similar: $2,000,000–$19,999,994
$12,150,82455
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗GENOCEA BIOSCIENCES, INC.DirectorJul 2, 2013D/A$30,500,000
similar: $2,000,000–$19,999,994
$30,500,00021
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Protagonist Therapeutics, IncDirectorJun 11, 2013D$18,040,000
similar: $2,000,000–$19,999,994
$7,000,0004
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗AQUINOX PHARMACEUTICALS (USA) INCDirectorApr 1, 2013D$20,999,962
similar: $500,000–$7,000,000
$13,999,9757
similar: 2–14
No minimum reported
similar: $5,000–$50,000
EDGAR ↗Aldeyra Therapeutics, Inc.DirectorJan 3, 2013D$8,787,906
similar: $2,000,000–$19,999,994
$4,793,6662
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗GENOCEA BIOSCIENCES, INC.DirectorOct 11, 2012D$30,500,000
similar: $2,000,000–$19,999,994
$15,250,00021
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗CATALYST BIOSCIENCES INCDirectorSep 25, 2012D$18,593,361
similar: $2,000,000–$19,999,994
$13,407,65821
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗PhaseBio Pharmaceuticals IncDirectorJun 18, 2012D/A$48,524,067
similar: $2,000,000–$19,999,994
$48,524,06717
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ISCIENCE INTERVENTIONAL CORPDirectorJan 31, 2012D$5,000,000
similar: $829,831–$9,999,998
$2,759,18512
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗Eiger BioPharmaceuticals, Inc.DirectorDec 22, 2011D$500,000
similar: $2,000,000–$19,999,994
$500,0006
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Eiger BioPharmaceuticals, Inc.DirectorNov 16, 2011D$500,000
similar: $2,000,000–$19,999,994
$330,0006
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Eiger BioPharmaceuticals, Inc.DirectorOct 28, 2011D$200,000
similar: $2,000,000–$19,999,994
$200,0006
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗AQUINOX PHARMACEUTICALS (USA) INCDirectorSep 26, 2011D$3,536,035
similar: $1,694,259–$16,000,000
$3,536,0356
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗Eiger BioPharmaceuticals, Inc.DirectorSep 1, 2011D$250,000
similar: $2,000,000–$19,999,994
$250,0006
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗ISCIENCE INTERVENTIONAL CORPDirectorAug 18, 2011D$3,000,000
similar: $829,831–$9,999,998
$3,000,0001
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗Eiger BioPharmaceuticals, Inc.DirectorJul 12, 2011D$400,000
similar: $1,694,259–$16,000,000
$400,0002
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗ISCIENCE INTERVENTIONAL CORPDirectorMay 17, 2011D$6,000,000
similar: $829,831–$9,999,998
$5,335,54512
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗AQUINOX PHARMACEUTICALS (USA) INCDirectorFeb 11, 2011D$4,724,298
similar: $1,694,259–$16,000,000
$4,724,2986
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗AQUINOX PHARMACEUTICALS INCDirectorFeb 11, 2011D$9
similar: $1,694,259–$16,000,000
$96
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗PhaseBio Pharmaceuticals IncDirectorDec 6, 2010D/A$25,300,001
similar: $2,000,000–$19,999,994
$25,300,00112
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Eiger BioPharmaceuticals, Inc.DirectorOct 28, 2010D$4,000,000
similar: $1,694,259–$16,000,000
$2,500,0007
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗ISCIENCE INTERVENTIONAL CORPDirectorSep 21, 2010D/A$10,000,000
similar: $829,831–$9,999,998
$5,087,96518
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗ISCIENCE INTERVENTIONAL CORPDirectorAug 11, 2010D$3,601,069
similar: $829,831–$9,999,998
$3,601,06915
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗AQUINOX PHARMACEUTICALS INCDirectorJun 25, 2010D$6
similar: $1,694,259–$16,000,000
$61
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗AQUINOX PHARMACEUTICALS (USA) INCDirectorJun 25, 2010D$3,531,483
similar: $1,694,259–$16,000,000
$3,531,4831
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗AQUINOX PHARMACEUTICALS INCDirectorApr 16, 2010D$9
similar: $1,694,259–$16,000,000
$95
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗AQUINOX PHARMACEUTICALS (USA) INCDirectorApr 15, 2010D$6,227,549
similar: $1,694,259–$16,000,000
$4,827,5495
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗PhaseBio Pharmaceuticals IncDirectorJan 5, 2010D$25,300,001
similar: $2,000,000–$19,999,994
$10,120,00012
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Eiger BioPharmaceuticals, Inc.DirectorDec 17, 2009D$6,500,000
similar: $1,694,259–$16,000,000
$3,500,0006
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗Eiger BioPharmaceuticals, Inc.DirectorSep 10, 2009D/A$24,631,114
similar: $1,694,259–$16,000,000
$21,800,0026
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗CATALYST BIOSCIENCES INCDirectorDec 8, 2008D$40,399,998
similar: $2,000,000–$19,999,994
$40,399,99810
similar: 2–16
No minimum reported
similar: $10,000–$50,000

Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.

"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); Other Health Care / 506(b) (4,189 filings); Biotechnology / 506(b) (3,253 filings); Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Connections as of Oct 23, 2026, 5:45 PM ET

Listed alongside — 40 names on the same filings (0 management entities, 40 people)

People and management entities the issuers listed as related persons on the same Form D filings as Asish Xavier. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.

  • Thong Le — 13 shared filings (6 issuers) · roles as listed: Executive Officer, Director, Promoter · also listed on 8 other issuers
  • Steve Gillis — 13 shared filings (6 issuers) · roles as listed: Director, Executive Officer, Promoter · also listed on 9 other issuers
  • Joel S. Marcus — 11 shared filings (6 issuers) · role as listed: Director · also listed on 12 other issuers
  • David Schubert — 10 shared filings (6 issuers) · roles as listed: Executive Officer, Promoter · also listed on 3 other issuers
  • Rebecque Laba — 8 shared filings (1 issuer) · role as listed: Executive Officer · also listed on 1 other issuer
  • Krisztina Zsebo — 8 shared filings (1 issuer) · roles as listed: Executive Officer, Director · also listed on 2 other issuers
  • Andrew E. Senyei — 8 shared filings (1 issuer) · role as listed: Director · also listed on 2 other issuers
  • Kenneth R. Chien — 8 shared filings (1 issuer) · role as listed: Director
  • Anthony B. Evnin — 8 shared filings (1 issuer) · role as listed: Director
  • Kenneth Galbraith — 8 shared filings (2 issuers) · role as listed: Director · also listed on 3 other issuers
  • David J. Main — 8 shared filings (2 issuers) · roles as listed: Executive Officer, Director, Promoter · also listed on 1 other issuer
  • Daniel Levitt — 8 shared filings (2 issuers) · role as listed: Director
  • Nassim Usman — 7 shared filings (1 issuer) · roles as listed: Executive Officer, Director · also listed on 3 other issuers
  • Jeff Himawan — 7 shared filings (1 issuer) · role as listed: Director · also listed on 5 other issuers
  • Lindsay Rayle — 7 shared filings (5 issuers) · roles as listed: Executive Officer, Promoter · also listed on 4 other issuers
  • Ralph Christoffersen — 7 shared filings (1 issuer) · role as listed: Director · also listed on 6 other issuers
  • Augustine Lawlor — 7 shared filings (1 issuer) · role as listed: Director · also listed on 15 other issuers
  • Ashutosh Chilkoti — 6 shared filings (1 issuer) · roles as listed: Director, Executive Officer · also listed on 1 other issuer
  • Guy Fish — 6 shared filings (1 issuer) · role as listed: Director · also listed on 2 other issuers
  • Stephen Majlath — 6 shared filings (2 issuers) · role as listed: Executive Officer
  • James Sullivan — 6 shared filings (4 issuers) · role as listed: Director · also listed on 2 other issuers
  • Ian Howes — 6 shared filings (3 issuers) · role as listed: Executive Officer · also listed on 2 other issuers
  • Clay Thorp — 6 shared filings (1 issuer) · role as listed: Director · also listed on 18 other issuers
  • Harold Selick — 6 shared filings (2 issuers) · role as listed: Director · also listed on 2 other issuers
  • Peter A. Thompson — 5 shared filings (1 issuer) · role as listed: Director · also listed on 28 other issuers
  • Michael Nash — 5 shared filings (1 issuer) · roles as listed: Director, Executive Officer · also listed on 48 other issuers
  • Wilfred Jaeger — 5 shared filings (1 issuer) · role as listed: Director · also listed on 3 other issuers
  • James Barrett — 5 shared filings (1 issuer) · role as listed: Director · also listed on 6 other issuers
  • Josh Resnick — 5 shared filings (1 issuer) · role as listed: Director · also listed on 3 other issuers
  • Kristine Johnson — 5 shared filings (1 issuer) · role as listed: Director
  • Graham Crooke — 5 shared filings (1 issuer) · role as listed: Director · also listed on 1 other issuer
  • Justin Klein — 5 shared filings (1 issuer) · role as listed: Director · also listed on 3 other issuers
  • Robert A. Ingram — 5 shared filings (1 issuer) · role as listed: Director · also listed on 8 other issuers
  • Peter Moldt — 5 shared filings (1 issuer) · role as listed: Director · also listed on 10 other issuers
  • M. Johnston Erwin — 5 shared filings (3 issuers) · role as listed: Director
  • Michael Powell — 5 shared filings (1 issuer) · role as listed: Director · also listed on 8 other issuers
  • R. Sanders Williams — 5 shared filings (1 issuer) · role as listed: Director · also listed on 1 other issuer
  • Kendall Mohler — 4 shared filings (2 issuers) · role as listed: Executive Officer · also listed on 3 other issuers
  • Fred A. Middleton — 4 shared filings (1 issuer) · role as listed: Director · also listed on 14 other issuers
  • Anne Sandan — 4 shared filings (1 issuer) · role as listed: Executive Officer · also listed on 1 other issuer

Other offering types (Regulation A and Regulation Crowdfunding)

None found in sources searched.

Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.

Export this report as PDF (members · included free during the launch period)

Change history

No corrections have been requested for this page.

Facts from public records only, each linked to its source. No ratings, no opinions. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Asish Xavier appears on a new Form D, or when a court case or SEC action is matched to them. See plans →